A Study in Sepsis Patients With Renal Failure

Sepsis Clinical Trial

Official title:

A Phase-IIa, Double-blind, Randomized, Placebo-controlled Study on the Safety and Early Efficacy of Alkaline Phosphatase in Sepsis Patients With Renal Failure

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00511186
• Other study ID #: AP REN 01-01
• Status: Terminated
• Phase: Phase 2
• First received: August 2, 2007
• Last updated: March 30, 2012
• Start date: May 2008
• Est. completion date: December 2009

Study information

• Verified date: March 2012
• Source: AM-Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety and tolerability of AP in sepsis patients with renal failure and to investigate the effect of AP on inflammatory and clinical parameters in sepsis patients with renal failure.

Description:

RATIONALE FOR THE STUDY

A previous clinical study conducted in centers in The Netherlands and Belgium have shown a substantial clinical benefit of AP treatment in patients with sepsis and associated acute renal failure (see Introduction above). The latter results require confirmation in a prospective study, as the current subject of this Protocol.

Choice of Drugs

The proposed study medication (AP) is identical to the study medication used in the previous clinical study in sepsis patients with single or multiple end-organ failure. Since there is no current proven treatment for these patients, the controls (as in previous studies) is placebo.

Choice of patient population

The aim is to enroll a maximum of 26 patients positive for sepsis with an APACHE score of ≥20 and ≤28 (determined within 24 hours of entry), and who will be analyzed on an intention to treat (ITT) basis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 36
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients between the age of 18 and 80 years.

• Proven or suspected infection.

• Two out of four SIRS criteria of systemic inflammation, existing for less than 24 hours after admission in the intensive care unit, as follows:

• Core temperature higher then 38 degree Celsius or lower then 36 degree Celsius.

• Heart rate above 90 beats/min (unless the patient has a medical condition known to increase heart rate or is receiving treatment that would prevent tachycardia).

• Respiratory rate above 20 breaths/min, a PaCO2 lower then 32mmHg or the use of mechanical ventilation for an acute respiratory process.

• White-cell count above 12,000/mm3 or below 4,000/mm3 or a differential count showing >10 percent immature neutrophils.

• Acute renal failure, defined as

• Rise in serum creatinine level to =150µmol/L within the previous 48 hours, in the absence of primary underlying renal disease OR

• Minimally a stage 1 Kidney Injury according to AKIN creatinine criteria:

Increase in serum creatinine =26.2µmol/L (0.3mg/dL) or increase to =150% (=1.5 -fold) from baseline in the previous 48 hours in the absence of primary underlying renal disease and where baseline creatinine is less than 150 µmol/L) OR

• Minimally a stage 1 Kidney Injury according to AKIN Urine Output criteria: Urine Output of = 0.5mg/kg/h for =6h and following adequate fluid resuscitation when applicable, in the absence of underlying primary renal disease and where baseline creatinine is less than 150µmol/L)

• Written informed consent obtained prior to any study intervention.

Exclusion Criteria:

• Pregnant women or nursing mothers and fecund females who are not on effective contraception (chemical: pill; or mechanical: IUD)

• Patients already on dialysis (RTT) at entry

• Known HIV (sero-positive) patients

• Patients receiving immunosuppressant therapy or on chronic high doses of steroids equivalent to prednisone 1mg/Kg/day

• Patients expected to have rapidly fatal disease within 24 hours

• Known confirmed gram-positive sepsis

• Known confirmed fungal sepsis

• Acute pancreatitis with no established source of infection

• Patients not expected to survive for 28 days due to other medical conditions such as end-stage neoplasm or other diseases

• Participation in another investigational study within 90 days prior to start of the study which might interfere with this study

• Any previous administration of active study medication.

• Known allergy for dairy (bovine) products including cow milk.

• Sepsis without renal failure as defined in the Entry Criteria.

• History of chronic renal failure or history of persistent creatinine level equal or greater than 150umol/L prior to entry for reasons other than the current sepsis condition".

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bacterial Infections
• Bacterial Infections and Mycoses
• Renal Insufficiency
• Sepsis
• Toxemia

Intervention

Drug:
• Placebo
placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
• BIAP
AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H

Locations

Country	Name	City	State
Belgium	University Medical Center Antwerp (UZA)	Antwerp
Belgium	Cliniques Universitaires Saint Luc-UCL	Brussels
Belgium	ULB Hopital Erasme	Brussels
Belgium	Universitair Ziekenhuis Brussel	Brussels
Netherlands	Jeroen Bosch Ziekenhuis lokatie GZG	's-Hertogenbosch
Netherlands	VU University Medical Center	Amsterdam
Netherlands	Canisius Wilhelmina Ziekenhuis	Nijmegen
Netherlands	UMC Nijmegen University Medical Center St Radboud	Nijmegen	Gelderland
Netherlands	Isala Clinics	Zwolle	Overijssel

Sponsors (1)

Lead Sponsor	Collaborator
AM-Pharma

Countries where clinical trial is conducted

Belgium,  Netherlands, 

References & Publications (1)

Pickkers P, Heemskerk S, Schouten J, Laterre PF, Vincent JL, Beishuizen A, Jorens PG, Spapen H, Bulitta M, Peters WH, van der Hoeven JG. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placeb — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Haematology, biochemistry, and microbiological evaluation. Adverse event monitoring.		28 Days	Yes
Secondary	To investigate the effect of AP on inflammatory parameters in sepsis patients with renal failure.		28 Days	No
Secondary	To investigate the effect of AP on clinical variables in sepsis patients with renal failure.		28 Days	No
Secondary	To investigate the effect of AP on renal function markers in sepsis patients with renal failure.		28 Days	No

External Links

•   Link